Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 2Phase 2 2Phase 1 1

Status

Completed 5Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 7

Sponsor

Cancer Type

Genitourinary 7

Conditions

Prostatic Neoplasms 240Neoplasm Metastasis 20Neoplasms 11Prostatic Neoplasms, Castration-Resistant 7Prostate Cancer Metastatic 7Metastatic Castration-resistant Prostate Cancer 5Pain 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Metastatic Castration-Resistant Prostate Cancer 3Testicular Neoplasms 2Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Myeloproliferative Disorders 2Multiple Myeloma 2Metastatic Castration Resistant Prostate Cancer 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Neutrophilic, Chronic 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2Kidney Neoplasms 2

Interventions

enzalutamide 7Prednisone 7cabazitaxel 6Radiosurgery 6Docetaxel 5Androgen Antagonists 4Abiraterone Acetate 4XRP6258 2Standard of Care 2talazoparib 1sipuleucel-T 1rucaparib 1pembrolizumab 1olaparib 1gallium 68 PSMA-11 1fludrocortisone acetate 1darolutamide 1apalutamide 1Zuclomiphene 1Radiotherapy, Image-Guided 1Radiotherapy 1Prednisolone 1Positron Emission Tomography Computed Tomography 1Pluvicto 1Midazolam 1Lutetium-177 1Lutetium 1Lenograstim 1LY3023414 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Prostate Cancer Metastatic × Prednisone × Genitourinary × Clear all
NCT06136624 2026-05-05

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,310 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT02913196 2026-04-20

Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC

Weill Medical College of Cornell University

Phase 1 Completed
16 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT02485691 2022-05-27

CARD

Sanofi

Phase 4 Completed
255 enrolled 21 charts
Genitourinary

Prostate Cancer Metastatic

NCT02961257 2022-05-12

CABASTY

Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie

Phase 3 Completed
196 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT02379390 2019-06-21

PRIMCAB

Sanofi

Phase 2 Terminated
8 enrolled 8 charts
Genitourinary

Prostate Cancer Metastatic

NCT01718353 2017-11-20

TAXYNERGY

Sanofi

Phase 2 Completed
63 enrolled 13 charts
Genitourinary

Prostate Cancer Metastatic

NCT02074137 2016-06-02

Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer

Sanofi

Phase 4 Completed
10 enrolled
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡